Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. Analysts use their in-depth research expertise, industry knowledge, and industry connections to figure out how well companies are doing every quarter.
Once they stumble upon something that could change the course of that company’s stock, they come out with analyst updates. These are usually in the form of an upgrade or downgrade, or simply an update on a previously assigned rating.
For retail investors, going through these reports saves a lot of time. This is why we came up with 10 stocks that analysts are talking about this week. To come up with the list of 10 stocks that analysts are talking about, we considered companies that received an analyst upgrade or coverage in the last 5 days.
10. Cytokinetics Incorporated (NASDAQ:CYTK)
Cytokinetics Incorporated is a late-stage pharmaceutical company committed to developing, commercializing, and discovering inhibitors and muscle activators. The financial research firm Stifel started analyst coverage of CYTK with a Buy rating due to its new promising drug, aficamten, promising an exciting couple of years ahead.
According to Stifel, aficamten is an extraordinary drug with a high competitive bar. Even outside the US, the drug is set to bring in millions of dollars of revenue for the company. In December, one of the company’s partners transferred the rights for the drug in China, Taiwan, and Hong Kong to Sanofi. CYTK is set to receive $150 million in a one-time payment and somewhere between $10-$20 million in sales. In Japan, the company has struck a similar deal with Bayer. In this way, CYTK can now focus on marketing the drug in the US while leaving its international operations to companies that have a better global presence.
The stock is down 43% in the last year, though that has a lot to do with Novartis walking away from an M&A deal. Apart from the promise of aficamten, new M&A activity cannot be ruled out and forms one of the components of Stifel’s bullish thesis on the stock.
9. Himax Technologies Inc. (NASDAQ:HIMX)
Himax Technologies Inc. is a fabless semiconductor company that operates in Non-Driver products and Driver IC segments. The company offers ePaper devices, industrial displays, display driver integrated circuits (ICs), automotive, and other products. TF International Securities’ analysts believe HIMX is expected to gain significantly from Taiwan Semiconductor’s (TSM) AI and Silicon Photonics advancement.
HIMX is set to be a beneficiary of TSM’s COUPE (Compact Universal Photonic Engine), a system that integrates photonics and electronics. The company has a TTM revenue of less than a billion dollars but it is set to report $1.16 billion in revenue in 2026, $1.42 billion in 2027, and $2.4 billion in 2028. This is well above what the current Wall Street consensus expects the company to achieve.
As positive as the above development is, the stock is already up 46% so far this month, which suggests a lot of these developments are getting priced in and investors will want to tread carefully before taking a big position in the stock.
Hedge Fund Resource Center